Investors sold shares of Bristol-Myers Squibb Company (NYSE:BMY) on strength during trading hours on Tuesday. $42.92 million flowed into the stock on the tick-up and $262.07 million flowed out of the stock on the tick-down, for a money net flow of $219.15 million out of the stock. Of all companies tracked, Bristol-Myers Squibb had the 0th highest net out-flow for the day. Bristol-Myers Squibb traded up $0.91 for the day and closed at $62.52

A number of research firms recently commented on BMY. Barclays lifted their target price on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Jefferies Group cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price for the company. in a research note on Monday, October 16th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Leerink Swann lifted their target price on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Finally, Citigroup lifted their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $64.93.

The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $102,326.49, a PE ratio of 21.12, a PEG ratio of 2.37 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the business posted $0.77 earnings per share. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.23% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Massey Quick Simon & CO. LLC increased its holdings in Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth $122,000. Tradewinds Capital Management LLC increased its holdings in Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares in the last quarter. Atlantic Trust LLC purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth $111,000. Finally, AllSquare Wealth Management LLC purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth $134,000. 69.69% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Investors Sell Shares of Bristol-Myers Squibb (BMY) on Strength (BMY)” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/30/investors-sell-shares-of-bristol-myers-squibb-bmy-on-strength-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.